Crossmark

Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial

Crossref DOI link: https://doi.org/10.1038/s41416-018-0036-7

Published Online: 2018-06-14

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Shi, Tingyan

Jiang, Rong

Yu, Jinjin

Yang, Huijuan

Tu, Dongsheng

Dai, Zhiyuan

Shen, Yang

Zhang, Yuqin

Cheng, Xi

Jia, Huixun

Tu, Ruiqin

Wang, Huaying

Tang, Jie

Luan, Yuting

Cai, Shumo

Zang, Rongyu https://orcid.org/0000-0002-1334-2398
License Information

Text and Data Mining valid from 2018-06-14
More Information

Article History

Received: 6 September 2017

Revised: 22 January 2018

Accepted: 26 January 2018

First Online: 14 June 2018

Conflict of interest

: The authors declare that they have no conflict of interest.